Advanced search

Vol 71, No 5 (2020)
Review paper
Published online: 2020-10-30

open access

View PDF Download PDF file
Page views 1622
Article views/downloads 1491
Get Citation

Connect on Social Media

Connect on Social Media

An overview of biological research on hypoxia-inducible factors (HIFs)

Zhe Liu1, Zixuan Wu2, Yuxin Fan1, Yudong Fang1
DOI: 10.5603/EP.a2020.0064
Pubmed: 33202030
Endokrynol Pol 2020;71(5):432-440.

Abstract

Hypoxia-inducible factors (HIFs), as a family of transcription factors involved in the cellular response to hypoxia, are key regulatory factors in the regulation mechanism of an organism’s response to hypoxia. A large number of studies have shown that HIFs are closely related to the angiogenesis, erythropoiesis, cell metabolism, and autophagy of organisms, as well as the occurrence and development of tumours. Therefore, it is of great significance to further study HIFs to understand and treat tumours or other related diseases. This paper summarises the structure, oxygen-dependent degradation mechanism, non-oxygen-dependent degradation mechanism, transcriptional activation mechanism, relevant signalling pathways, and inhibitors of HIFs, in order to provide new clues for the treatment of tumour, vascular, and other related diseases. 

Keywords: HIFsbiological research

Article available in PDF format

View PDF Download PDF file

References

  1. Storz G, Imlay JA. Oxidative stress. Curr Opin Microbiol. 1999; 2(2): 188–194.
    CrossRefPubMed
  2. Wiesener MS, Maxwell PH. HIF and oxygen sensing; as important to life as the air we breathe? Ann Med. 2003; 35(3): 183–190.
    CrossRefPubMed
  3. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev. 2000; 14(16): 1983–1991.
    PubMed
  4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992; 12(12): 5447–5454.
    CrossRefPubMed
  5. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993; 268(29): 21513–21518.
    PubMed
  6. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270(3): 1230–1237.
    CrossRefPubMed
  7. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270(3): 1230–1237.
    CrossRefPubMed
  8. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10): 721–732.
    CrossRefPubMed
  9. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004; 5(6): 437–448.
    CrossRefPubMed
  10. Sharp F, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004; 5(6): 437–448.
    CrossRefPubMed
  11. Semenza GL. Targeting hypoxia-inducible factor 1 to stimulate tissue vascularization. J Investig Med. 2016; 64(2): 361–363.
    CrossRefPubMed
  12. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012; 148(3): 399–408.
    CrossRefPubMed
  13. Semenza GL. Vascular responses to hypoxia and ischemia. Arterioscler Thromb Vasc Biol. 2010; 30(4): 648–652.
    CrossRefPubMed
  14. Hirao M, Hashimoto J, Yamasaki N, et al. Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J Bone Miner Metab. 2007; 25(5): 266–276.
    CrossRefPubMed
  15. Pinheiro C, Miranda-Gonçalves V, Longatto-Filho A, et al. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4. Cell Cycle. 2016; 15(11): 1462–1470.
    CrossRefPubMed
  16. Serocki M, Bartoszewska S, Janaszak-Jasiecka A, et al. miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target. Angiogenesis. 2018; 21(2): 183–202.
    CrossRefPubMed
  17. Klaus A, Fathi O, Tatjana TW, et al. Expression of Hypoxia-Associated Protein HIF-1α in Follicular Thyroid Cancer is Associated with Distant Metastasis. Pathol Oncol Res. 2018; 24(2): 289–296.
    CrossRefPubMed
  18. Zhu Gh, Huang C, Feng Zz, et al. Hypoxia-induced snail expression through transcriptional regulation by HIF-1α in pancreatic cancer cells. Dig Dis Sci. 2013; 58(12): 3503–3515.
    CrossRefPubMed
  19. Duan C. Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am J Physiol Cell Physiol. 2016; 310(4): C260–C269.
    CrossRefPubMed
  20. Lando D, Gorman JJ, Whitelaw ML, et al. Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation. Eur J Biochem. 2003; 270(5): 781–790.
    CrossRefPubMed
  21. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270(3): 1230–1237.
    CrossRefPubMed
  22. Jiang BH, Zheng JZ, Leung SW, et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997; 272(31): 19253–19260.
    CrossRefPubMed
  23. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001; 294(5545): 1337–1340.
    CrossRefPubMed
  24. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292(5516): 468–472.
    CrossRefPubMed
  25. Lee JW, Bae SH, Jeong JW, et al. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med. 2004; 36(1): 1–12.
    CrossRefPubMed
  26. Mahon PC, Hirota K, Semenza GL. FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001; 15(20): 2675–2686.
    CrossRefPubMed
  27. Shi H, Wu Y, et al. Ubiquitin ligase Siah1 promotes the migration and invasion of human glioma cells by regulating HIF-1α signaling under hypoxia. Oncol Rep. 2015; 33(3): 1185–1190.
    CrossRefPubMed
  28. Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood. 1998; 92(7): 2260–2268.
    PubMed
  29. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1): 43–54.
    CrossRefPubMed
  30. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001; 107(1): 43–54.
    CrossRefPubMed
  31. Gu BJ, Zhang W, Worthington RA, et al. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem. 2001; 276(14): 11135–11142.
    CrossRefPubMed
  32. Xilouri M, Stefanis L. Chaperone mediated autophagy in aging: Starve to prosper. Ageing Res Rev. 2016; 32: 13–21.
    CrossRefPubMed
  33. Hubbi ME, Hu H, Ahmed I, et al. Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J Biol Chem. 2013; 288(15): 10703–10714.
    CrossRefPubMed
  34. Adam MG, Matt S, Christian S, et al. SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status. Cell Cycle. 2015; 14(23): 3734–3747.
    CrossRefPubMed
  35. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001; 107(1): 1–3.
    CrossRefPubMed
  36. Semenza GL. Physiology meets biophysics: Visualizing the interaction of hypoxia-inducible factor 1  with p300 and CBP. Proc Natl Acad Sci USA. 2002; 99(18): 11570–11572.
    CrossRefPubMed
  37. Lando D, Peet DJ, Gorman JJ, et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16(12): 1466–1471.
    CrossRefPubMed
  38. Martin A, Patlan MC, Flores MR. The Role of Hypoxia-Inducible Factors in Cancer Resistance. J Cell Signal. 2017; 2(1): 154.
    CrossRef
  39. Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 2002; 295(5556): 858–861.
    CrossRefPubMed
  40. Kung AL, Wang S, Klco JM, et al. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000; 6(12): 1335–1340.
    CrossRefPubMed
  41. Mylonis I, Chachami G, Samiotaki M, et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem. 2006; 281(44): 33095–33106.
    CrossRefPubMed
  42. Kietzmann T, Mennerich D, Dimova EY. Hypoxia-Inducible Factors (HIFs) and Phosphorylation: Impact on Stability, Localization, and Transactivity. Front Cell Dev Biol. 2016; 4: 11.
    CrossRefPubMed
  43. Joo HY, Yun M, Jeong J, et al. SIRT1 deacetylates and stabilizes hypoxia-inducible factor-1α (HIF-1α) via direct interactions during hypoxia. Biochem Biophys Res Commun. 2015; 462(4): 294–300.
    CrossRefPubMed
  44. Lee SoD, Kim W, Jeong JW, et al. AK-1, a SIRT2 inhibitor, destabilizes HIF-1α and diminishes its transcriptional activity during hypoxia. Cancer Lett. 2016; 373(1): 138–145.
    CrossRefPubMed
  45. Subbaramaiah K, Iyengar NM, Morrow M, et al. Prostaglandin E down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection. J Biol Chem. 2019; 294(1): 361–371.
    CrossRefPubMed
  46. Calgani A, Delle Monache S, Cesare P, et al. Leptin contributes to long-term stabilization of HIF-1α in cancer cells subjected to oxygen limiting conditions. Cancer Lett. 2016; 376(1): 1–9.
    CrossRefPubMed
  47. Hubbi ME, Hu H, Gilkes DM, et al. Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem. 2013; 288(29): 20768–20775.
    CrossRefPubMed
  48. Schöning JP, Monteiro M, Gu W. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α. Clin Exp Pharmacol Physiol. 2017; 44(2): 153–161.
    CrossRefPubMed
  49. Chen J, Bai M, Ning C, et al. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene. 2016; 35(19): 2506–2517.
    CrossRefPubMed
  50. Wang Hu, Zhao Li, Zhu LT, et al. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog. 2014; 53 Suppl 1: E107–E118.
    CrossRefPubMed
  51. Shi Yh, Wang Yx, You Jf, et al. [Activation of HIF-1 by bFGF in breast cancer: role of PI-3K and MEK1/ERK pathways]. Zhonghua Yi Xue Za Zhi. 2004; 84(22): 1899–1903.
    PubMed
  52. Shi YH, Wang YX, Bingle L, et al. In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways. J Pathol. 2005; 205(4): 530–536.
    CrossRefPubMed
  53. Zhang Q, Oh CK, Messadi DV, et al. Hypoxia-induced HIF-1 alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp Cell Res. 2006; 312(2): 145–155.
    CrossRefPubMed
  54. Ao Q, Su W, Guo S, et al. SENP1 desensitizes hypoxic ovarian cancer cells to cisplatin by up-regulating HIF-1α. Sci Rep. 2015; 5: 16396.
    CrossRefPubMed
  55. Zhou J, Sun C. SENP1/HIF-1α axis works in angiogenesis of human dental pulp stem cells. J Biochem Mol Toxicol. 2020; 34(3): e22436.
    CrossRefPubMed
  56. Wang X, Liang X, Liang H, et al. SENP1/HIF-1α feedback loop modulates hypoxia-induced cell proliferation, invasion, and EMT in human osteosarcoma cells. J Cell Biochem. 2018; 119(2): 1819–1826.
    CrossRefPubMed
  57. Cui CP, Wong CCL, Kai AKL, et al. SENP1 promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation and SENP1/HIF-1α positive feedback loop. Gut. 2017; 66(12): 2149–2159.
    CrossRefPubMed
  58. Wu H, Huang S, Chen Z, et al. Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway. Mol Med Rep. 2015; 12(5): 6467–6474.
    CrossRefPubMed
  59. Zhang Y, Liu D, Hu H, et al. HIF-1α/BNIP3 signaling pathway-induced-autophagy plays protective role during myocardial ischemia-reperfusion injury. Biomed Pharmacother. 2019; 120: 109464.
    CrossRefPubMed
  60. Peng Y, Fang Z, Liu M, et al. Testosterone induces renal tubular epithelial cell death through the HIF-1α/BNIP3 pathway. J Transl Med. 2019; 17(1): 62.
    CrossRefPubMed
  61. Liu XW, Lu MK, Zhong HT, et al. Panax Notoginseng Saponins Attenuate Myocardial Ischemia-Reperfusion Injury Through the HIF-1α/BNIP3 Pathway of Autophagy. J Cardiovasc Pharmacol. 2019; 73(2): 92–99.
    CrossRefPubMed
  62. Wu H, Huang S, Chen Z, et al. Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway. Mol Med Rep. 2015; 12(5): 6467–6474.
    CrossRefPubMed
  63. Zhao Yi, Chen G, Zhang W, et al. Autophagy regulates hypoxia-induced osteoclastogenesis through the HIF-1α/BNIP3 signaling pathway. J Cell Physiol. 2012; 227(2): 639–648.
    CrossRefPubMed
  64. Berra E, Milanini J, Richard D, et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol. 2000; 60(8): 1171–1178.
    CrossRefPubMed
  65. Huang CY, Hsieh YL, Ju DT, et al. Attenuation of Magnesium Sulfate on CoCl₂-Induced Cell Death by Activating ERK1/2/MAPK and Inhibiting HIF-1α via Mitochondrial Apoptotic Signaling Suppression in a Neuronal Cell Line. Chin J Physiol. 2015; 58(4): 244–253.
    CrossRefPubMed
  66. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 2000; 468(1): 53–58.
    CrossRefPubMed
  67. Hannken T, Schroeder R, Zahner G. Reactive oxygen species stimulate p44/42 mitogen-activated protein kinase and induce p27(Kip1): role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol. 2000; 11: 1387–1397.
    PubMed
  68. Guan R, Wang J, Li Z, et al. Sodium Tanshinone IIA Sulfonate Decreases Cigarette Smoke-Induced Inflammation and Oxidative Stress via Blocking the Activation of MAPK/HIF-1α Signaling Pathway. Front Pharmacol. 2018; 9: 263.
    CrossRefPubMed
  69. Gao L, Wu Gj, Liu B, et al. Up-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cells. PLoS One. 2013; 8(12): e84127.
    CrossRefPubMed
  70. Yokoe S, Nakagawa T, Kojima Y, et al. Indomethacin-induced intestinal epithelial cell damage is mediated by pVHL activation through the degradation of collagen I and HIF-1α. Biochem Biophys Res Commun. 2015; 468(4): 671–676.
    CrossRefPubMed
  71. Minet E, Mottet D, Michel G, et al. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999; 460(2): 251–256.
    CrossRefPubMed
  72. Liu NN, Zhao N, Cai Na. The effect and mechanism of celecoxib in hypoxia-induced survivin up-regulation in HUVECs. Cell Physiol Biochem. 2015; 37(3): 991–1001.
    CrossRefPubMed
  73. Xu WN, Zheng HL, Yang RZ, et al. HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through PDK1/AKT/mTOR Signaling Pathway. Front Endocrinol (Lausanne). 2019; 10: 922.
    CrossRefPubMed
  74. Chi Y, Luo Q, Song Y, et al. Circular RNA circPIP5K1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/HIF-1α regulation. J Cell Biochem. 2019; 120(11): 19019–19030.
    CrossRefPubMed
  75. Shen Y, Chen G, Zhuang L, et al. ARHGAP4 mediates the Warburg effect in pancreatic cancer through the mTOR and HIF-1α signaling pathways. Onco Targets Ther. 2019; 12: 5003–5012.
    CrossRefPubMed
  76. Shen B, Mei M, Pu Y, et al. Necrostatin-1 Attenuates Renal Ischemia and Reperfusion Injury via Meditation of HIF-1α/mir-26a/TRPC6/PARP1 Signaling. Mol Ther Nucleic Acids. 2019; 17: 701–713.
    CrossRefPubMed
  77. Yang R, Zhu Yi, Wang Y, et al. HIF-1α/PDK4/autophagy pathway protects against advanced glycation end-products induced vascular smooth muscle cell calcification. Biochem Biophys Res Commun. 2019; 517(3): 470–476.
    CrossRefPubMed
  78. Zhu L, Mu J, Wu Y, et al. Role of HIF-1α in Cold Ischemia Injury of Rat Donor Heart Via the miR-21/PDCD4 Pathway. Transplant Proc. 2020; 52(1): 383–391.
    CrossRefPubMed
  79. Gai X, Zhou P, Xu M, et al. Hyperactivation of IL-6/STAT3 pathway leaded to the poor prognosis of post-TACE HCCs by HIF-1α/SNAI1 axis-induced epithelial to mesenchymal transition. J Cancer. 2020; 11(3): 570–582.
    CrossRefPubMed
  80. Liu H, Shi C, Deng Y. MALAT1 affects hypoxia-induced vascular endothelial cell injury and autophagy by regulating miR-19b-3p/HIF-1α axis. Mol Cell Biochem. 2020; 466(1-2): 25–34.
    CrossRefPubMed
  81. Yu LM, Zhang WH, Han XX, et al. Hypoxia-Induced ROS Contribute to Myoblast Pyroptosis during Obstructive Sleep Apnea via the NF-B/HIF-1 Signaling Pathway. Oxid Med Cell Longev. 2019; 2019: 4596368.
    CrossRefPubMed
  82. Jeong W, Rapisarda A, Park SR, et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2014; 73(2): 343–348.
    CrossRefPubMed
  83. Zhang H, Pu J, Qi T, et al. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene. 2014; 33(3): 387–397.
    CrossRefPubMed
  84. Qu H, Zheng L, Song H, et al. microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5'-untranslated region in neuroblastoma. Oncotarget. 2016; 7(26): 40657–40673.
    CrossRefPubMed
  85. Hutt DM, Roth DM, Vignaud H, et al. The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition. PLoS One. 2014; 9(8): e106224.
    CrossRefPubMed
  86. Coltella N, Valsecchi R, Ponente M, et al. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia. Clin Cancer Res. 2015; 21(16): 3685–3694.
    CrossRefPubMed
  87. Ma Li, Li G, Zhu H, et al. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett. 2014; 355(1): 96–105.
    CrossRefPubMed
  88. Shukla SK, Purohit V, Mehla K, et al. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell. 2017; 32(1): 71–87.e7.
    CrossRefPubMed
  89. Yu T, Tang Bo, Sun X. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy. Yonsei Med J. 2017; 58(3): 489–496.
    CrossRefPubMed
  90. Wu D, Potluri N, Lu J, et al. Structural integration in hypoxia-inducible factors. Nature. 2015; 524(7565): 303–308.
    CrossRefPubMed
  91. Miranda E, Nordgren IK, Male AL, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013; 135(28): 10418–10425.
    CrossRefPubMed
  92. Scheuermann TH, Li Q, Ma HW, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol. 2013; 9(4): 271–276.
    CrossRefPubMed
  93. Wilkins SE, Abboud MI, Hancock RL, et al. Targeting Protein-Protein Interactions in the HIF System. ChemMedChem. 2016; 11(8): 773–786.
    CrossRefPubMed
  94. Latha MS, Saddala MS. Molecular docking based screening of a simulated HIF-1 protein model for potential inhibitors. Bioinformation. 2017; 13(11): 388–393.
    CrossRefPubMed
  95. Portugal J. Challenging transcription by DNA-binding antitumor drugs. Biochem Pharmacol. 2018; 155: 336–345.
    CrossRefPubMed
  96. Jayatunga MKP, Thompson S, McKee TC, et al. Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). Eur J Med Chem. 2015; 94: 509–516.
    CrossRefPubMed
  97. Reece KM, Richardson ED, Cook KM, et al. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. Mol Cancer. 2014; 13: 91.
    CrossRefPubMed
  98. Zimna A, Kurpisz M. Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed Res Int. 2015; 2015: 549412.
    CrossRefPubMed
  99. Masoud GN, Wang J, Chen J, et al. Design, Synthesis and Biological Evaluation of Novel HIF1α Inhibitors. Anticancer Res. 2015; 35(7): 3849–3859.
    PubMed
  100. Jiang L, Shi S, Shi Q, et al. Similarity in the functions of HIF-1α and HIF-2α proteins in cervical cancer cells. Oncol Lett. 2017; 14(5): 5643–5651.
    CrossRefPubMed
  101. Guan Z, Ding C, Du Y, et al. HAF drives the switch of HIF-1α to HIF-2α by activating the NF-κB pathway, leading to malignant behavior of T24 bladder cancer cells. Int J Oncol. 2014; 44(2): 393–402.
    CrossRefPubMed
  102. Martínez-Sáez O, Gajate Borau P, Alonso-Gordoa T, et al. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. Crit Rev Oncol Hematol. 2017; 111: 117–123.
    CrossRefPubMed
  103. Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017; 17(12): 774–785.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note